These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7571996)

  • 1. Safety and recovery of mononine in multiple-dose, high-dose regimens.
    White GC
    Acta Haematol; 1995; 94 Suppl 1():53-7; discussion 57-8. PubMed ID: 7571996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
    White GC; Shapiro AD; Kurczynski EM; Kim HC; Bergman GE
    Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates.
    Kim HC; McMillan CW; White GC; Bergman GE; Horton MW; Saidi P
    Blood; 1992 Feb; 79(3):568-75. PubMed ID: 1531035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and in vivo properties of high purity factor IX concentrates.
    Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
    Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-purity factor IX concentrates for treatment of hemophilia B: relative purity and thrombogenic potential.
    Limentani SA; Gowell KP; Deitcher SR
    Acta Haematol; 1995; 94 Suppl 1():12-7. PubMed ID: 7571989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B.
    Hoots WK; Leissinger C; Stabler S; Schwartz BA; White G; Dasani H; Massion C; Negrier C; Schindel F; Schulman S
    Haemophilia; 2003 Mar; 9(2):164-72. PubMed ID: 12614367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Properties of factor IX concentrates.
    Berntorp E
    Acta Haematol; 1995; 94 Suppl 1():8-11. PubMed ID: 7571997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved safety from plasma derivatives: purification and viral elimination characteristics of mononine.
    Feldman F; Chandra S; Huang C
    Acta Haematol; 1995; 94 Suppl 1():25-32; discussion 33-4. PubMed ID: 7571992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog.
    Keith JC; Ferranti TJ; Misra B; Frederick T; Rup B; McCarthy K; Faulkner R; Bush L; Schaub RG
    Thromb Haemost; 1995 Jan; 73(1):101-5. PubMed ID: 7740479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of continuous infusion of Mononine during five surgical procedures in three hemophilic patients.
    Ménart C; Petit PY; Attali O; Massignon D; Dechavanne M; Négrier C
    Am J Hematol; 1998 Jun; 58(2):110-6. PubMed ID: 9625577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of high doses of a monoclonal antibody-purified factor IX concentrate. The Mononine Study Group.
    Warrier I; Kasper CK; White GC; Shapiro AD; Bergman GE
    Am J Hematol; 1995 May; 49(1):92-4. PubMed ID: 7741147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis in factor IX deficiency product and patient variation.
    Kisker CT; Eisberg A; Schwartz B;
    Haemophilia; 2003 May; 9(3):279-84. PubMed ID: 12694518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant treatment with factor IX concentrates and antifibrinolytics in hemophilia B.
    Djulbegovic B; Hannan MM; Bergman GE
    Acta Haematol; 1995; 94 Suppl 1():43-7; discussion 48. PubMed ID: 7571994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous infusion of factor concentrates: review of use in hemophilia A and demonstration of safety and efficacy in hemophilia B.
    Martinowitz UP; Schulman S
    Acta Haematol; 1995; 94 Suppl 1():35-42. PubMed ID: 7571993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro characterization of high purity factor IX concentrates for the treatment of hemophilia B.
    Limentani SA; Gowell KP; Deitcher SR
    Thromb Haemost; 1995 Apr; 73(4):584-91. PubMed ID: 7495063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current management of hemophilia B.
    Roberts HR; Eberst ME
    Hematol Oncol Clin North Am; 1993 Dec; 7(6):1269-80. PubMed ID: 8294316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys.
    McCarthy K; Stewart P; Sigman J; Read M; Keith JC; Brinkhous KM; Nichols TC; Schaub RG
    Thromb Haemost; 2002 May; 87(5):824-30. PubMed ID: 12038784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of factor IX activity differ from that of factor IX antigen in patients with haemophilia B receiving high-purity factor IX replacement.
    Liebman HA; Rosenwald-Zuckerman T; Retzios A; Yasmin S; Kasper CK
    Haemophilia; 1999 May; 5(3):174-80. PubMed ID: 10444284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B.
    Ewenstein BM; Joist JH; Shapiro AD; Hofstra TC; Leissinger CA; Seremetis SV; Broder M; Mueller-Velten G; Schwartz BA;
    Transfusion; 2002 Feb; 42(2):190-7. PubMed ID: 11896334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.
    Lissitchkov T; Matysiak M; Zavilska K; Laguna P; Gercheva L; Antonov A; Moret A; Caunedo P; Aznar JA; Woodward MK; Páez A
    Haemophilia; 2013 Sep; 19(5):674-8. PubMed ID: 23647607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.